PITTSBURGH — Mylan and a partnering company will be able to sell a generic version of a cancer drug starting in summer 2015, under a court settlement announced Tuesday.
Mylan said that it and Banner Pharmacaps had reached a settlement agreement with Eisai and a subsidiary of Valeant Pharmaceuticals International to resolve a lawsuit filed over their generic version of Targretin (bexarotene) capsules in the 75-mg strength. The drug is used to treat certain forms of T-cell lymphoma.
Under the agreement, Mylan and Banner can start selling a generic version of Targretin starting in July 2015. Targretin in the 75-mg strength had sales of about $53.6 million during the 12-month period that ended in September, according to IMS Health.